Peiyong J. Guan

Singapore, 138672, Singapore

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers.

Journal: Science translational medicine
Published: April 01, 2026

Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Journal: Nature communications
Published: October 21, 2025

Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma.

Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma.

Journal: Cancer discovery
Published: April 02, 2025

PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor by inducing senescence in cholangiocarcinoma.

PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor by inducing senescence in cholangiocarcinoma.

Journal: International journal of biological sciences
Published: January 23, 2025

Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling.

Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling.

Journal: NPJ breast cancer
Published: August 10, 2024

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Journal: Scientific reports
Published: August 05, 2024

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.

CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 10, 2024

Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability.

Comprehensive molecular characterization of collecting duct carcinoma for therapeutic vulnerability.

Journal: EMBO molecular medicine
Published: February 19, 2024

Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.

Aristolochic acid-related renal cell carcinoma exhibits a distinct tumor-immune microenvironment favoring response to immune checkpoint blockade.

Journal: The Journal of pathology
Published: February 18, 2024

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: January 30, 2024

Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.

Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches.

Journal: Cancers
Published: January 11, 2024

CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma.

CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma.

Journal: Cancer letters
Published: December 15, 2023
Showing 1-12 of 48

Last Updated: 09/26/2026